ETENRU

Roche Eesti Osaühing

Osaühing · 11124024 · Registrisse kantud

Download PDFDownload CSV

Activity

Roche Eesti Osaühing is a medium enterprise in professional, scientific & technical, with declared activity “Kogu muu mujal liigitamata kutse-, teadus- ja tehnikaalane tegevus” (EMTAK 74991). Annual revenue stands at 43.94 M € with 29 employees, ranks #3 of 38,293 in professional, scientific & technical.

Professional, scientific & technical

Public procurement

Public-sector contracts this company has won via the Estonian Public Procurement Register.

Contract value
108.96 M €
Contracts
68
Buyers
5
Most recent
2026-01-15
BuyerValueYear
Antineoplastilised ravimid
Ravimid
sihtasutus Tartu Ülikooli Kliinikum6.79 M €2024
Antineoplastilised ravimid
Antineoplastilised ained
sihtasutus Tartu Ülikooli Kliinikum6.54 M €2026
Kasvajavastased ained, immunosupressandid, oftalmoloogias kasutatavad ained, hingamisteede obstruktiivsete haiguste raviks kasutatavad ained, migreenivastased ained
Ravimid
sihtasutus Põhja-Eesti Regionaalhaigla6.00 M €2024
Kasvajavastased ained, immunosupressandid, oftalmoloogias kasutatavad ained, hingamisteede obstruktiivsete haiguste raviks kasutatavad ained, migreenivastased ained
Ravimid
sihtasutus Põhja-Eesti Regionaalhaigla6.00 M €2024
Kasvajavastased ained, immunosupressandid, oftalmoloogias kasutatavad ained, hingamisteede obstruktiivsete haiguste raviks kasutatavad ained, migreenivastased ained
Ravimid
sihtasutus Põhja-Eesti Regionaalhaigla6.00 M €2024
Immunosupressantide ja immunostimulaatorite ostmine
Antineoplastilised ja immuunmoduleerivad ained
Aktsiaselts Lääne-Tallinna Keskhaigla5.07 M €2024
Kasvajavastased ained, immunosupressandid, oftalmoloogias kasutatavad ained, hingamisteede obstruktiivsete haiguste raviks kasutatavad ained, migreenivastased ained
Ravimid
sihtasutus Põhja-Eesti Regionaalhaigla5.00 M €2025
Monoklonaalsed antikehad, immuunosupressandid, teised astmavastased ained süsteemseks kasutamiseks, teised dermatoloogilised preparaadid
Ravimid
sihtasutus Põhja-Eesti Regionaalhaigla5.00 M €2023
Monoklonaalsed antikehad, immuunosupressandid, teised astmavastased ained süsteemseks kasutamiseks, teised dermatoloogilised preparaadid
Ravimid
sihtasutus Põhja-Eesti Regionaalhaigla4.50 M €2023
Kasvajavastased ja endokrinoloogilised ained (L01-L02)
Ravimid
Aktsiaselts Ida-Tallinna Keskhaigla4.38 M €2025

Court decisions

Supreme Court (Riigikohus) decisions naming this company. Source: Riigikohus.

Overview (2024)

Revenue
43.94 M €
▲ 17.4%YoY
▲ 1000+×above industry median
Profit
1.87 M €
▲ 84.5%YoY
Profit margin
4.2%
Employees
29
▲ 3.6%YoY
Revenue per employee
1.52 M €
Cost per employee
115.4 k €
Equity
12.67 M €

Growth

Revenue
43.94 M €
▲ 17.4%
1y
▲ 12.2%
3y CAGR
—
5y CAGR
Profit
1.87 M €
▲ 84.5%
1y
▲ 21.9%
3y CAGR
—
5y CAGR
Employees
29
▲ 3.6%
1y
▲ 2.4%
3y CAGR
—
5y CAGR

Trends

Revenue trend
43.94 M €
Profit trend
1.87 M €
Headcount trend
29

Revenue to profit

43.9 M €Revenue−3.3 M €Labor cost−38.7 M €Other costs1.9 M €Profit

Capital structure

  • Equity47%
  • Liabilities53%

Financials

YearRevenueGrowthProfitMarginEmployeesRevenue per employeeEquity
2024 ✓43.94 M €▲ 17.4%1.87 M €4%291.52 M €12.67 M €
2023 ✓37.44 M €▼ 0.3%1.01 M €3%281.34 M €9.82 M €
2022 ✓37.55 M €▲ 20.8%1.18 M €3%291.29 M €8.81 M €
2021 ✓31.07 M €▲ 5.3%1.03 M €3%271.15 M €7.63 M €
2020 ✓29.52 M €—819.0 k €3%251.18 M €6.60 M €
2019 ✓———————

Similar companies

Same industry, comparable revenue.

Official announcements

Bankruptcy notices, liquidation notices, and other official statements about the company.

View announcements on Ametlikud Teadaanded →

Court rulings

Public court decisions where the company or its registry code is mentioned.

Search court rulings on Riigi Teataja →

General info

Shareholders

Equity holders ranked by ownership percentage.

Beneficial owners

Individuals who ultimately own or control the company.

Board (4)